Effect of HFNO on Spontaneous Ventilation in Obese Patients During Analgo-sedation for Vitrectomy
Sedation Complication, Obesity, Hypoxic Respiratory Failure
About this trial
This is an interventional treatment trial for Sedation Complication focused on measuring Noninvasive Ventilation, Obesity, Moderate sedation, Adult, High-flow nasal oxygenation, Vitrectomy, Airway management
Eligibility Criteria
Inclusion Criteria:
- Normal weight and obese patients (18<BMI<30 kg/m2, 30≤BMI<35 kg/m2, BMI≥35 kg/m2)
- Moderate intravenous analgo-sedation
- Pars plana vitrectomy
Exclusion Criteria:
- Higher anesthesia risk patients (ASA III)
- Conventional vitrectomy
- Diseases of peripheral blood vessels
- Hematological diseases
- Psychiatric diseases
- Sideropenic anemia
- Patient's refusal
- Ongoing chemotherapy or irradiation
- Remifentanyl and Xomolix allergies
Sites / Locations
- University clinical hospital centre ZagrebRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator: 18<BMI<30 - LFNO
Active Comparator: 30≤BMI<35 kg/m2 - LFNO
Active Comparator: BMI≥35 kg/m2 - LFNO
Experimental: 18<BMI<30 kg/m2 - HFNO
Experimental: 30≤BMI<35 kg/m2 - HFNO
Experimental: BMI≥35 kg/m2 - HFNO
Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%